PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom
Assaf, C.; Illidge, T.M.; Waser, N.; He, M.; Li, T.; Zomas, A.; Bent-Ennakhil, N.; Little, M.; Ortiz-Romero, P.L.; Pimpinelli, N.; Dalal, M.; Bagot, M. A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/ Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom. Cancers2023, 15, 5669.
Assaf, C.; Illidge, T.M.; Waser, N.; He, M.; Li, T.; Zomas, A.; Bent-Ennakhil, N.; Little, M.; Ortiz-Romero, P.L.; Pimpinelli, N.; Dalal, M.; Bagot, M. A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/ Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom. Cancers 2023, 15, 5669.
Assaf, C.; Illidge, T.M.; Waser, N.; He, M.; Li, T.; Zomas, A.; Bent-Ennakhil, N.; Little, M.; Ortiz-Romero, P.L.; Pimpinelli, N.; Dalal, M.; Bagot, M. A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/ Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom. Cancers2023, 15, 5669.
Assaf, C.; Illidge, T.M.; Waser, N.; He, M.; Li, T.; Zomas, A.; Bent-Ennakhil, N.; Little, M.; Ortiz-Romero, P.L.; Pimpinelli, N.; Dalal, M.; Bagot, M. A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/ Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom. Cancers 2023, 15, 5669.
Abstract
(1) Background: Most patients with mycosis fungoides (MF), a form of cutaneous T-cell lym-phoma (CTCL), develop relapsed/refractory (R/R) disease following front-line systemic therapy. This report describes treatment patterns and outcomes from the subpopulation with R/R MF. (2) Methods: This observational, retrospective, cohort study analysed patient records (1984–2016) from 27 clinical sites in Eurpe. Outcomes included treatments received, response to first-, second- and third-line treatment, overall survival (OS), and progression-free survival (PFS). (3) Results: Of 104 patients with MF, 100 received second-line and 61 received third-line therapy. Median (range) times from start of first-line therapy to first R/R MF and from first to second R/R MF were 11.2 (0.3–166.5) and 13.5 (0.0–174.6) months, respectively. Second-and third-line treatment options varied and comprised systemic therapies (85% and 79% of patients, respectively), radio-therapy (32% and 34%, respectively) and topical therapies (48% and 36%, respectively). Median (95% confidence interval [CI]) OS from the diagnosis of first R/R MF was 11.5 (6.5–not reached [NR]) years and was higher with non-chemotherapy (NR) versus chemotherapy (6.5 years); es-timated median PFS (95% CI) from the time of first R/R MF was 1.3 (1.0–2.1) years. (4) Conclu-sion: High rates of R/R disease were observed after second- and third-line treatments in this re-al-world cohort, with longer median OS in patients receiving non-chemotherapy versus chemo-therapy. Following the standard management of MF and using recently approved targeted therapies can help improve patient outcomes in advanced-stage MF.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.